VALN Latest Press Releases

-- November 10, 2026 --

Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ Globe Newswire 1:00 AM

-- November 9, 2026 --

Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2 Globe Newswire 1:00 AM

-- November 4, 2026 --

Valneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026 Globe Newswire 11:45 AM

-- October 14, 2026 --

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences Globe Newswire 11:45 AM

-- October 7, 2026 --

Valneva Provides Update on IXCHIQ in the United Kingdom Globe Newswire 4:00 PM

-- August 14, 2026 --

Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency Globe Newswire 1:00 AM

Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency Business Wire 1:00 AM

-- August 13, 2026 --

Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates Globe Newswire 1:00 AM

-- July 22, 2026 --

Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026 Globe Newswire 11:45 AM

-- June 25, 2026 --

Valneva Announces Successful Outcome of its Annual General Meeting Globe Newswire 11:45 AM

Market Data Delayed 15 Minutes